Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010702 | 0.85 | CES1 (0.53) | GSK3BCASP3CASP2CASP7CASP6 | |
| SCHEMBL11229952 | 0.82 | TLR9 (0.50) | POLBGSK3BMEN1KMT2ACASP3 | |
| SCHEMBL29410213 | 0.80 | CYP3A4 (0.45) | POLBGSK3BMEN1KMT2ANR1H3 | |
| SCHEMBL4649466 | 0.76 | POLB (0.65) | POLBMEN1KMT2ANR1H3NR1H2 | |
| SCHEMBL28871744 | 0.75 | GSK3B (0.44) | POLBGSK3BMEN1KMT2ACASP3 | |
| SCHEMBL16754925 | 0.74 | GSK3B (0.62) | POLBGSK3BMEN1KMT2ACASP3 | |
| SCHEMBL2403872 | 0.71 | POLB (0.51) | POLBMEN1KMT2ANR1H3NR1H2 | |
| Hydrochloric Acid SCHEMBL15282882 | 0.71 | MAPT (0.55) | POLBGSK3BMEN1KMT2ACASP3 | |
| SCHEMBL135332 | 0.69 | GSK3B (0.56) | POLBGSK3BMEN1KMT2ACASP3 | |
| SCHEMBL11860388 | 0.69 | ADORA2A (0.62) | POLBMEN1KMT2ANR1H3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | claimed |
| WO-2017081676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | PHARMATWOB (IL) | 2017-05-18 | — | — | WO | disclosed |
| US-20130216608-A1 | Airway Administration of Angiogenesis Inhibitors | TRIFOILIUM APS (DK) | 2013-08-22 | — | — | US | disclosed |
| EP-2613773-A2 | AIRWAY ADMINISTRATION OF ANGIOGENESIS INHIBITORS | Trifoilium ApS (DK) | 2013-07-17 | — | — | EP | disclosed |
| US-20130101688-A1 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | YALE UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012031603-A2 | AIRWAY ADMINISTRATION OF ANGIOGENESIS INHIBITORS | DANISH MEDICAL CONSULTS APS (DK) | 2012-03-15 | — | — | WO | disclosed |
| US-7534455-B2 | Herbal composition PHY906 and its use in chemotherapy | YALE UNIVERSITY (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1812028-A2 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | YALE UNIVERSITY (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006053049-A2 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | YALE UNIVERSITY (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050196473-A1 | Herbal composition PHY906 and its use in chemotherapy | KADMON CORPORATION, LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216608-A1 | Airway Administration of Angiogenesis Inhibitors | VEGFA, SERPINB1, MMP1 | POLB 570/4885GSK3B 2790/4885MEN1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.